Trajenta

Trajenta

linagliptin

Manufacturer:

Boehringer Ingelheim

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Linagliptin
Indications/Uses
Adult patients w/ type 2 DM to improve glycaemic control in conjunction w/ diet & exercise as monotherapy or as add-on to metformin, sulphonylureas, thiazolidinediones, insulin (w/ or w/o metformin &/or sulphonylurea), or metformin + sulfonylureas or metformin + empagliflozin.
Dosage/Direction for Use
Administration
May be taken with or without food.
Contraindications
Special Precautions
Do not use in patients w/ type 1 diabetes or for the treatment of diabetic ketoacidosis. Discontinue if pancreatitis & bullous pemphigoid are suspected. Hypoglycemia; concomitant use w/ sulphonylurea. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Nasopharyngitis; hypersensitivity, angioedema, urticaria; hypoglycemia, hypertriglyceridaemia, hyperlipidaemia; cough; pancreatitis, constipation, mouth ulceration; rash; bullous pemphigoid; increased wt, lipase & amylase.
Drug Interactions
Decreased steady-state AUC & Cmax w/ rifampicin. Increased plasma AUC & Cmax of simvastatin.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH05 - linagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Trajenta FC tab 5 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in